The Effects AZD8529 on Ketamine-induced Impairment of Working Memory in Healthy Volunteers
Early Phase 1
Completed
- Conditions
- HealthyMemory Impairment
- Interventions
- Drug: Placebo to match AZD8529
- Registration Number
- NCT00985933
- Lead Sponsor
- AstraZeneca
- Brief Summary
The purpose of this study is to assess if ketamine will induce, in healthy volunteers, impairment of working memory and if the drug AZD8529 will block the effects of ketamine on working memory as assessed by functional magnetic resonance imaging (fMRI).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
- Right handed
- 12th grade education or equivalent
- Able to read and write English as primary language
Exclusion Criteria
- History of head injury
- Substance abuse or dependence
- History of claustrophobia
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- CROSSOVER
- Arm && Interventions
Group Intervention Description 1 AZD8529 180 mg of AZD8529 1 Placebo to match AZD8529 180 mg of AZD8529 2 Placebo to match AZD8529 50 mg AD8529 3 AZD8529 Placebo 3 Placebo to match AZD8529 Placebo 2 AZD8529 50 mg AD8529
- Primary Outcome Measures
Name Time Method fMRI 3 Ketamine Infusion 3
- Secondary Outcome Measures
Name Time Method Clinician Administered Dissociative States Scale (CADSS) Positive and Negative Syndrome Scale (PANSS) Laboratory assessment: electrocardiogram (ECG), physical exam, vital signs, collection of adverse events
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie AZD8529's modulation of mGluR2/3 to counteract ketamine-induced prefrontal cortex activation impairment in healthy volunteers?
How does AZD8529's efficacy in mitigating ketamine-induced working memory deficits compare to other mGluR2/3 positive allosteric modulators in preclinical or clinical studies?
Which biomarkers correlate with AZD8529's reversal of NMDA receptor antagonist-induced prefrontal cortex dysfunction in healthy subjects?
What are the safety profiles and adverse event management strategies for AZD8529 combined with ketamine in early-phase human trials?
Are there other AstraZeneca mGluR modulators in development for cognitive impairment linked to NMDA receptor antagonism, and how do their mechanisms differ from AZD8529?
Trial Locations
- Locations (1)
Research Site
🇺🇸New Haven, Connecticut, United States
Research Site🇺🇸New Haven, Connecticut, United States